Anne Thushara Matthias
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne Thushara Matthias has a total of 201 co-authors. Here are the top co-authors by number of shared publications:
- Khung Keong Yeo
National Heart Center Singapore, Singapore, Singapore
4 shared publications Shamini Prathapan
Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka
4 shared publications- Stephen J. Nicholls
Victorian Heart Institute, Monash University, Clayton, Australia
4 shared publications Adam J. Nelson
Victorian Heart Institute, Monash University, Clayton, Vic, Australia
3 shared publicationsAlan Fong
3 shared publicationsAmbuj Roy
Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India
3 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
Unveiling the national epidemic of uncontrolled blood pressure in a low middle-income country: a nation wide multicenter study
- 23 October 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
Open AccessUnveiling the national epidemic of uncontrolled blood pressure in a low middle-income country: a nation wide multicenter study
- Open Access
- 22 October 2026
- Published by Springer Nature in Journal of Rare Diseases
- Vol. 5 (1) , 107
Adult presentation of gaucher disease: diagnostic and therapeutic challenges in a resource-limited setting
Background: Gaucher disease is an autosomal recessive lysosomal storage disorder caused by biallelic pathogenic variant in GBA1, resulting in deficient glucocerebrosidase activity and accumulation of glycosylceramide-laden macrophages. It is most reported among the Ashkenazi Jewish population. Reported cases in Sri Lanka are rare and have largely been confined to the paediatric population, with adult presentations being exceptionally uncommon. Adult recognition may be difficult where specialist investigations and disease-specific therapies are difficult to access. Case presentation: A 52-year-old Buddhist monk presented with generalized tonic-clonic epilepsy since 12 years of age presented after a further seizure while taking sodium valproate 500 mg daily. He also complained of abdominal discomfort and had a one-month history of mild cognitive impairment. On examination, he showed pallor, and splenomegaly without hepatomegaly or lymphadenopathy. Investigations revealed pancytopenia and 20 cm spleen with multiple low-attenuation splenic gaucheromas, an isolated lytic skull lesion, peripheral retinal bone-spicule-like pigmentation, and biclonal IgG-kappa paraproteins. Bone marrow examination showed macrophages morphologically consistent with Gaucher cells. Fluorometric dried-blood-spot testing demonstrated reduced beta-glucosidase activity of 0.67 nmol/hr/mL (laboratory reference interval 2.3–18.4). Confirmatory leukocyte or fibroblast enzyme testing, GBA1 analysis, PSAP analysis, and disease-specific biomarkers were unavailable in the country. No gaze palsy, oculomotor apraxia, ataxia, pyramidal signs, parkinsonism, or peripheral neuropathy was identified; The clinical phenotype classified as neuronopathic Gaucher disease with existing clinical evidence. Disease-specific therapy was considered at a multidisciplinary meeting but was not initiated because of patient preference, limited access, cost and uncertainty regarding benefit for the longstanding epilepsy. The patient continued symptomatic treatment with clinical and hematological surveillance. Discussion: Gaucher disease is rare in adulthood. The disease may involve multiple organ systems, while ocular manifestations are uncommon. Close clinical follow-up is important for early detection of complications. The potential systemic benefits of treatment must be distinguished from its limitations for neurological disease. This case illustrates the challenges of recognizing, confirming and treating Gaucher disease in a resource-limited setting. Clinical trial number: Not applicable.
- 22 October 2026
- Published by Springer Nature in Journal of Rare Diseases
- Vol. 5 (1) , 107
Open AccessAdult presentation of gaucher disease: diagnostic and therapeutic challenges in a resource-limited setting
Background: Gaucher disease is an autosomal recessive lysosomal storage disorder caused by biallelic pathogenic variant in GBA1, resulting in deficient glucocerebrosidase activity and accumulation of glycosylceramide-laden macrophages. It is most reported among the Ashkenazi Jewish population. Reported cases in Sri Lanka are rare and have largely been confined to the paediatric population, with adult presentations being exceptionally uncommon. Adult recognition may be difficult where specialist investigations and disease-specific therapies are difficult to access. Case presentation: A 52-year-old Buddhist monk presented with generalized tonic-clonic epilepsy since 12 years of age presented after a further seizure while taking sodium valproate 500 mg daily. He also complained of abdominal discomfort and had a one-month history of mild cognitive impairment. On examination, he showed pallor, and splenomegaly without hepatomegaly or lymphadenopathy. Investigations revealed pancytopenia and 20 cm spleen with multiple low-attenuation splenic gaucheromas, an isolated lytic skull lesion, peripheral retinal bone-spicule-like pigmentation, and biclonal IgG-kappa paraproteins. Bone marrow examination showed macrophages morphologically consistent with Gaucher cells. Fluorometric dried-blood-spot testing demonstrated reduced beta-glucosidase activity of 0.67 nmol/hr/mL (laboratory reference interval 2.3–18.4). Confirmatory leukocyte or fibroblast enzyme testing, GBA1 analysis, PSAP analysis, and disease-specific biomarkers were unavailable in the country. No gaze palsy, oculomotor apraxia, ataxia, pyramidal signs, parkinsonism, or peripheral neuropathy was identified; The clinical phenotype classified as neuronopathic Gaucher disease with existing clinical evidence. Disease-specific therapy was considered at a multidisciplinary meeting but was not initiated because of patient preference, limited access, cost and uncertainty regarding benefit for the longstanding epilepsy. The patient continued symptomatic treatment with clinical and hematological surveillance. Discussion: Gaucher disease is rare in adulthood. The disease may involve multiple organ systems, while ocular manifestations are uncommon. Close clinical follow-up is important for early detection of complications. The potential systemic benefits of treatment must be distinguished from its limitations for neurological disease. This case illustrates the challenges of recognizing, confirming and treating Gaucher disease in a resource-limited setting. Clinical trial number: Not applicable.
- Open Access
- 23 August 2026
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 74, 101934
The impact and evolution of environmental/occupational, behavioural, and metabolic risk factors on CVD burdens in the Asia–Pacific region from 1990 to 2023: a secondary analysis of the Global Burden of Disease Study 2023
- 23 August 2026
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 74, 101934
Open AccessThe impact and evolution of environmental/occupational, behavioural, and metabolic risk factors on CVD burdens in the Asia–Pacific region from 1990 to 2023: a secondary analysis of the Global Burden of Disease Study 2023
- Open Access
- 5 May 2026
- Published by Wolters Kluwer Health in International Journal of Noncommunicable Diseases
- Vol. 11 (3) , 238-246
Prevalence and risk factors for familial hypercholesterolemia in patients with premature coronary artery disease in a low- and middle-income South Asian setting
Background and Aims: Familial hypercholesterolemia (FH) is a common genetic disorder. The prevalence of FH in premature coronary artery disease (CAD) in Sri Lanka was unknown before this study. Materials and Methods: A cross-sectional study was conducted in 602 individuals aged 18–60 years with CAD. FH was diagnosed using the Dutch Lipid Clinic Network (DLCN) score. Results: The prevalence of definite FH was 0.67% (95% confidence interval [CI]: 0.18–1.7), with probable FH of 4.1% (95% CI: 2.7–6.1) and possible FH of 18.4% (95% CI: 15.4–21.7). The mean age at onset of early-onset CAD was 48.3 years (standard deviation [SD] = 6.9). The mean low-density lipoprotein cholesterol (LDL-C) levels were highest in the probable and definite FH groups: 260.5 mg/dL (SD = 39.2) and 420.7 mg/dL (SD = 129.3), respectively. The prevalence of diabetes and obesity was similar in patients with and without FH. Among those not on statins ( n = 352), the mean LDL-C was 118.6 mg/dL (SD = 23.9 mg/dL). Among the 250 patients on statins, the target LDL-C level of P = 0.001). Conclusions: FH is relatively common in patients with premature CAD. These results highlight the need to promote FH identification in patients with premature CAD.
- 5 May 2026
- Published by Wolters Kluwer Health in International Journal of Noncommunicable Diseases
- Vol. 11 (3) , 238-246
Open AccessPrevalence and risk factors for familial hypercholesterolemia in patients with premature coronary artery disease in a low- and middle-income South Asian setting
Background and Aims: Familial hypercholesterolemia (FH) is a common genetic disorder. The prevalence of FH in premature coronary artery disease (CAD) in Sri Lanka was unknown before this study. Materials and Methods: A cross-sectional study was conducted in 602 individuals aged 18–60 years with CAD. FH was diagnosed using the Dutch Lipid Clinic Network (DLCN) score. Results: The prevalence of definite FH was 0.67% (95% confidence interval [CI]: 0.18–1.7), with probable FH of 4.1% (95% CI: 2.7–6.1) and possible FH of 18.4% (95% CI: 15.4–21.7). The mean age at onset of early-onset CAD was 48.3 years (standard deviation [SD] = 6.9). The mean low-density lipoprotein cholesterol (LDL-C) levels were highest in the probable and definite FH groups: 260.5 mg/dL (SD = 39.2) and 420.7 mg/dL (SD = 129.3), respectively. The prevalence of diabetes and obesity was similar in patients with and without FH. Among those not on statins ( n = 352), the mean LDL-C was 118.6 mg/dL (SD = 23.9 mg/dL). Among the 250 patients on statins, the target LDL-C level of P = 0.001). Conclusions: FH is relatively common in patients with premature CAD. These results highlight the need to promote FH identification in patients with premature CAD.
- 23 March 2026
- Published by SAGE Publications in Tropical Doctor
Severe thrombocytopenia without major haemorrhage in dengue in a patient on dual antiplatelet therapy; a real world clinical experience
Dengue is endemic in tropical regions and bleeding, ranging from minor to life-threatening, is a dreaded complication. With the increasing incidence of atherosclerotic cardiovascular disease in low- to middle-income countries where Dengue is prevalent, whether to stop or continue antiplatelet agents in patients with thrombocytopenia is a clinical conundrum.
- 23 March 2026
- Published by SAGE Publications in Tropical Doctor
Severe thrombocytopenia without major haemorrhage in dengue in a patient on dual antiplatelet therapy; a real world clinical experience
Dengue is endemic in tropical regions and bleeding, ranging from minor to life-threatening, is a dreaded complication. With the increasing incidence of atherosclerotic cardiovascular disease in low- to middle-income countries where Dengue is prevalent, whether to stop or continue antiplatelet agents in patients with thrombocytopenia is a clinical conundrum.
- Open Access
- 2 December 2025
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
Cardiomyopathy and Gender Disparities in South Asian Countries: A Scoping Review
Cardiomyopathies, a diverse group of heart muscle diseases, pose a significant health challenge globally, particularly among South Asian populations. South Asian people exhibit unique genetic, socio-economic and lifestyle factors influencing disease prevalence and outcomes, often marked by pronounced gender disparities. This scoping review explores gender-based differences in cardiomyopathies in South Asia. It aims to identify socio-cultural and biological contributors to these disparities and to propose tailored strategies to address inequities. The scoping review identified pronounced disparities influenced by genetic, hormonal, socio-cultural and healthcare access factors, with significant gaps in gender-specific data. South Asian women face distinct challenges in cardiomyopathy management, including genetic predisposition, hormonal influences and socio-economic barriers. Cultural norms often delay diagnosis and treatment, leading to worse outcomes. Genetic variations, environmental influences and inadequate healthcare access further compound these gender disparities. Recommendations emphasise personalised interventions, public health policies for targeted screening, equitable healthcare access, and gender-sensitive interventions to improve outcomes for South Asian men and women.
- 2 December 2025
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
Open AccessCardiomyopathy and Gender Disparities in South Asian Countries: A Scoping Review
Cardiomyopathies, a diverse group of heart muscle diseases, pose a significant health challenge globally, particularly among South Asian populations. South Asian people exhibit unique genetic, socio-economic and lifestyle factors influencing disease prevalence and outcomes, often marked by pronounced gender disparities. This scoping review explores gender-based differences in cardiomyopathies in South Asia. It aims to identify socio-cultural and biological contributors to these disparities and to propose tailored strategies to address inequities. The scoping review identified pronounced disparities influenced by genetic, hormonal, socio-cultural and healthcare access factors, with significant gaps in gender-specific data. South Asian women face distinct challenges in cardiomyopathy management, including genetic predisposition, hormonal influences and socio-economic barriers. Cultural norms often delay diagnosis and treatment, leading to worse outcomes. Genetic variations, environmental influences and inadequate healthcare access further compound these gender disparities. Recommendations emphasise personalised interventions, public health policies for targeted screening, equitable healthcare access, and gender-sensitive interventions to improve outcomes for South Asian men and women.